Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
  • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
  • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
  • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
  • C07D277/28—Radicals substituted by nitrogen atoms
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/425—Thiazoles
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
  • A61P11/06—Antiasthmatics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
  • A61P13/12—Drugs for disorders of the urinary system of the kidneys
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/04—Antipruritics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/06—Antipsoriatics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
  • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
  • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P27/00—Drugs for disorders of the senses
  • A61P27/02—Ophthalmic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
  • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
  • A61P35/02—Antineoplastic agents specific for leukemia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
  • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
  • A61P7/06—Antianaemics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
  • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
  • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
  • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
  • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
  • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
  • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
  • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
  • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
  • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
  • C07D285/01—Five-membered rings
  • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
  • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
  • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
  • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
  • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
  • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
  • C07F9/02—Phosphorus compounds
  • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
  • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
  • C07F9/576—Six-membered rings
  • C07F9/58—Pyridine rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
  • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
  • C07F9/02—Phosphorus compounds
  • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
  • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
  • C07F9/6503—Five-membered rings
  • C07F9/65031—Five-membered rings having the nitrogen atoms in the positions 1 and 2
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
  • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
  • C07F9/02—Phosphorus compounds
  • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
  • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
  • C07F9/6509—Six-membered rings
  • C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
  • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
  • C07F9/02—Phosphorus compounds
  • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
  • C07F9/6527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
  • C07F9/653—Five-membered rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
  • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
  • C07F9/02—Phosphorus compounds
  • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
  • C07F9/6527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
  • C07F9/653—Five-membered rings
  • C07F9/65306—Five-membered rings containing two nitrogen atoms
  • C07F9/65312—Five-membered rings containing two nitrogen atoms having the two nitrogen atoms in positions 1 and 2
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
  • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
  • C07F9/02—Phosphorus compounds
  • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
  • C07F9/6527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
  • C07F9/653—Five-membered rings
  • C07F9/65306—Five-membered rings containing two nitrogen atoms
  • C07F9/65318—Five-membered rings containing two nitrogen atoms having the two nitrogen atoms in positions 1 and 3
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
  • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
  • C07F9/02—Phosphorus compounds
  • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
  • C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
  • C07F9/6539—Five-membered rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
  • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
  • C07F9/02—Phosphorus compounds
  • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
  • C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
  • C07F9/6539—Five-membered rings
  • C07F9/65392—Five-membered rings containing two nitrogen atoms
  • C07F9/65395—Five-membered rings containing two nitrogen atoms having the two nitrogen atoms in positions 1 and 2

Definitions

• the sphingosine-1-phosphate (S1P) receptors 1-5 constitute a family of seven transmembrane G-protein coupled receptors. These receptors, referred to as S1P-1 to S1P-5, are activated via binding by sphingosine-1-phosphate, which is produced by the sphingosine kinase-catalyzed phosphorylation of sphingosine.
• S1P receptors are cell surface receptors involved in a variety of cellular processes, including cell proliferation and differentiation, cell survival, cell invasion, lymphocyte trafficking, and cell migration. Sphingosine-1-phosphate is found in plasma and a variety of other tissues, and exerts autocrine and paracrine effects, including regulating the secretion of growth factors.
• S1P Stimulated protein kinase
• S1P-1 receptor activation of the S1P-1 receptor.
• S1P in vivo has been shown to cause hypotension and bradycardia, which are believed to be due to signaling through one or more of the other S1P receptors, i.e. S1P-2 to S1P-5. Accordingly, there is a need for compounds which are potent and selective agonists of the S1P-1 receptor.
• the present invention is directed to a compound of formula I:
• R 1 is hydrogen, halogen, cyano, alkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, aralkyl, heteroalykl, —O-alkyl, —O-aryl, —O-heteroaryl, —S-alkyl, alkylene-O-alkyl, alkylene-CO 2 H, alkylene-CO 2 alkyl, alkylSO 2 , alkylenesulfonyl, alkylene-CO-amino, alkylene-CO-alkylamino, alkylene-CO-dialkylamino, alkylene-NH—CO 2 H, alkylene-NH—CO 2 alkyl —CO 2 alkyl, —OH, —C(O)-alkyl, —C(O)O-alkyl, —CONH 2 , —CO-alkylamino, —CO-dialkylamino, amino, alkylamino,
• A is (C 1 -C 20 )alkylene, (C 2 -C 20 )alkenylene, or (C 2 -C 20 )alkynylene, each of which may be optionally substituted on carbon with 1, 2, or 3 groups selected from OH, CO 2 H, CO 2 alkyl, halogen, amino, alkylamino, dialkylamino, —O-alkyl, alkylene-O-alkyl, alkylene-OH, or alkylene-CO 2 H;
• X 1 is a bond or is CH 2 , O, —CH 2 O—, S, —S(O), —S(O) 2 , —C(O)—, —C(O)O—, or NR x , wherein R x is H ⁇ or (C 1 -C 6 )alkyl;
• R′ and R′′ are each independently hydrogen, halogen, alkyl optionally substituted on carbon with halogen, alkyl, or taken together with the carbon to which they are attached form C ⁇ O or a 3, 4, 5, or 6-membered ring, optionally containing 1 or 2 heteroatoms selected from ONH, N-alkyl, SO, or SO 2 , any of which may be optionally substituted on carbon with alkyl or halogen
• R 2 is cyano, alkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, aralkyl, heteroalykl, —O-alkyl, —O-aryl, —O-heteroaryl, aralkoxy, heteroaralkoxy, —S-alkyl, alkylene-O-alkyl, alkylene-CO 2 H, alkylene-CO 2 alkyl, alkylSO 2 , alkylenesulfonyl, alkylene-CO-amino, alkylene-CO-alkylamino, alkylene-CO-dialkylamino, alkylene-NH—CO 2 H, alkylene-NH—CO 2 alkyl —CO 2 alkyl, —OH, —C(O)-alkyl, —C(O)O-alkyl, —CONH 2 , —CO-alkylamino, —CO-dialkylamino, amino,
• R 3 is absent, hydrogen, halogen, cyano, alkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, aralkyl, heteroalykl, —O-alkyl, —O-aryl, —O-heteroaryl, aralkoxy, heteroaralkoxy, —S-alkyl, alkylene-O-alkyl, alkylene-CO 2 H, alkylene-CO 2 alkyl, alkylSO 2 , alkylenesulfonyl, alkylene-CO-amino, alkylene-CO-alkylamino, alkylene-CO-dialkylamino, alkylene-NH—CO 2 H, alkylene-NH—CO 2 alkyl —CO 7 alkyl, —OH, —C(O)-alkyl, —C(O)O-alkyl, —CONH 2 , —CO-alkylamino, —CO-
• aryl, heteroaryl, heterocyclo, or cycloalkyl any of which may be optionally substituted on carbon with 1, 2, or 3 groups selected form halogen, alkyl, O-alkyl, CO 2 H, CO 2 alkyl, halogen, amino, alkylamino, dialkylamino, —O-alkyl, alkylene-O-alkyl, alkylene-OH, or alkylene-CO 2 H, provided that
• R 4 is hydrogen, cyano, alkyl, aryl, heteroaryl, alkylene-O-alkyl, alkylene-OH, aryl, alkylene-O-alkyl, —CO 2 H, —CO 2 -alkyl, alkylene-CO 2 H, or alkylene-CO 2 -alkyl, alkylene-OC(O)R wherein R is hydrogen or alkyl; cycloalkyl, heterocycloalkyl, alkylene-NH 2 , alkylene-alkylamino, or alkylene-dialkylamino, any of which may be optionally substituted on carbon with 1, 2, or 3 groups selected from OH, CO 2 H, CO 2 alkyl, halogen, amino, alkylamino, dialkylamino, —O-alkyl, alkylene-O-alkyl, alkylene-OH, or alkylene-CO 2 H;
• R 5 and R 6 are each independently selected from the group consisting of hydrogen, alkyl, alkylene-OH, aryl, alkylene-O-alkyl, —CO 2 H, CO 2 -alkyl, alkylene-OC(O)alkyl, cycloalkyl, heterocyclo, —C(O)-alkyl, —C(O)-aryl, C(O)-aralkyl, —C(O)-Oalkyl, —C(O)-Oaryl, —C(O)-Oaralkyl, alkylene-amino, alkylene-alkylamino, and alkylene-dialkylamino, any of which may be optionally substituted on carbon with halogen, alkyl, hydroxyl, CO 2 H, CO 2 alkyl or alkoxy; or
• R 5 and R 6 together with the nitrogen to which they are attached, may form a 3, 4, 5, or 6-membered saturated or unsaturated ring, optionally containing 1 or 2 additional heteroatoms selected from O, S, NH, or N-alkyl, and optionally substituted on carbon with halogen, alkyl, hydroxyl, or alkoxy;
• R 7 is selected from the group consisting of —OH, —O-alkyl, alkylene-OH, —CO 2 H, alkylene-CO 2 H, —C(O)O-alkyl, -alkylene-CO 2 -alkyl, —C(O)O-aryl, —CH 2 ⁇ CHCO 2 H, —CH 2 ⁇ CHC(O)O-alkyl, —CH 2 ⁇ CHC(O)O-aryl, —OPO 2 R p1 R p2 , —OPO 3 R p1 R p2 , —CH 2 PO 3 R p1 R p2 , —OPO 2 (S)R p1 R p2 , and —C(Z′)(Z′′)PO 3 R p1 R p2 , any of which may be optionally substituted on carbon with halogen, alkyl, hydroxyl, carboxy, or alkoxy; and wherein
• Z′ is hydroxyl or halogen
• Z′′ is H or halogen
• R p1 , and R p2 are each independently hydrogen, C 1 -C 6 -alkyl, aryl, or one of the following groups:
• Y is heterocyclo or heteroaryl.
• R 2 is alkyl substituted with 1, 2 or 3 halo groups. In some embodiments, R 2 is trifluoromethyl.
• the present invention is directed to a compound of formula II:
• R 1 is hydrogen, halogen, cyano, alkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, aralkyl, heteroalykl, —O-alkyl, —O-aryl, —O-heteroaryl, —S-alkyl, alkylene-O-alkyl, alkylene-CO 2 H, alkylene-CO 2 alkyl, alkylSO 2 , alkylenesulfonyl, alkylene-CO-amino, alkylene-CO-alkylamino, alkylene-CO-dialkylamino, alkylene-NH—CO 2 H, alkylene-NH—CO 2 alkyl —CO 2 alkyl, —OH, —C(O)-alkyl, —C(O)O-alkyl, —CONH 2 , —CO-alkylamino, —CO-dialkylamino, amino, alkylamino,
• A is (C 1 -C 20 )alkylene, (C 2 -C 20 )alkenylene, or (C 2 -C 20 )alkynylene, each of which may be optionally substituted on carbon with 1, 2, or 3 groups selected from OH, CO 2 H, CO 2 alkyl, halogen, amino, alkylamino, dialkylamino, —O-alkyl, alkylene-O-alkyl, alkylene-OH, or alkylene-CO 2 H;
• X 1 is a bond or is CH 2 , O, —CH 2 O—, S, —S(O), —S(O) 2 , —C(O)—, —C(O)O—, or NR x , wherein R x is H or (C 1 -C 6 )alkyl;
• R′ and R′′ are each independently hydrogen, halogen, alkyl optionally substituted on carbon with halogen, alkyl, or taken together with the carbon to which they are attached form C ⁇ O or a 3, 4, 5, or 6-membered ring, optionally containing 1 or 2 heteroatoms selected from ONH, N-alkyl, SO, or SO 2 , any of which may be optionally substituted on carbon with alkyl or halogen
• R 3 is absent, hydrogen, halogen, cyano, alkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, aralkyl, heteroalykl, —O-alkyl, —O-aryl, —O-heteroaryl, aralkoxy, heteroaralkoxy, —S-alkyl, alkylene-O-alkyl, alkylene-CO 2 H, alkylene-CO 2 alkyl, alkylSO 2 , alkylenesulfonyl, alkylene-CO-amino, alkylene-CO-alkylamino, alkylene-CO-dialkylamino, alkylene-NH—CO 2 H, alkylene-NH—CO 2 alkyl —CO 2 alkyl, —OH, —C(O)-alkyl, —C(O)O-alkyl, —CONH 2 , —CO-alkylamino, —CO-
• aryl, heteroaryl, heterocyclo, or cycloalkyl any of which may be optionally substituted on carbon with 1, 2, or 3 groups selected form halogen, alkyl, O-alkyl, CO 2 H, CO 2 alkyl, halogen, amino, alkylamino, dialkylamino, —O-alkyl, alkylene-O-alkyl, alkylene-OH, or alkylene-CO 2 H, provided that
• R 4 is hydrogen, cyano, alkyl, aryl, heteroaryl, alkylene-O-alkyl, alkylene-OH, aryl, alkylene-O-alkyl, —CO 2 H, —CO 2 -alkyl, alkylene-CO 2 H, or alkylene-CO 2 -alkyl, alkylene-OC(O)R wherein R is hydrogen or alkyl; cycloalkyl, heterocycloalkyl, alkylene-NH 2 , alkylene-alkylamino, or alkylene-dialkylamino, any of which may be optionally substituted on carbon with 1, 2, or 3 groups selected from OH, CO 2 H, CO 2 alkyl, halogen, amino, alkylamino, dialkylamino, —O-alkyl, alkylene-O-alkyl, alkylene-OH, or alkylene-CO 2 H;
• R 5 and R 6 are each independently selected from the group consisting of hydrogen, alkyl, alkylene-OH, aryl, alkylene-O-alkyl, —CO 2 H, CO 2 -alkyl, alkylene-OC(O)alkyl, cycloalkyl, heterocyclo, —C(O)-alkyl, —C(O)-aryl, C(O)-aralkyl, —C(O)-Oalkyl, —C(O)—Oaryl, —C(O)—Oaralkyl, alkylene-amino, alkylene-alkylamino, and alkylene-dialkylamino, any of which may be optionally substituted on carbon with halogen, alkyl, hydroxyl, CO 2 H, CO 2 alkyl or alkoxy; or
• R 5 and R 6 together with the nitrogen to which they are attached, may form a 3, 4, 5, or 6-membered saturated or unsaturated ring, optionally containing 1 or 2 additional heteroatoms selected from O, S, NH, or N-alkyl, and optionally substituted on carbon with halogen, alkyl, hydroxyl, or alkoxy;
• R 7 is selected from the group consisting of —OH, —O-alkyl, -alkylene-OH, —CO 2 H, -alkylene-CO 2 H, —C(O)O-alkyl, -alkylene-CO 2 -alkyl, —C(O)O-aryl, —CH 2 ⁇ CHCO 2 H, —CH 2 ⁇ CHC(O)O-alkyl, —CH 2 ⁇ CHC(O)O-aryl, —OPO 2 R p1 R p2 , —OPO 3 R p1 R p2 , —CH 2 PO 3 R p1 R p2 , —OPO 2 (S)R p1 R p2 , and —C(Z′)(Z′′)PO 3 R p1 R p2 , any of which may be optionally substituted on carbon with halogen, alkyl, hydroxyl, carboxy, or alkoxy; and wherein
• Z′ is hydroxyl or halogen
• Z′′ is H or halogen
• R p1 and R p2 are each independently hydrogen, C 1 -C 6 -alkyl, aryl, or one of the following groups:
• Y is heterocyclo or heteroaryl.
• compounds of the present invention include compounds listed in the following table:
• the present invention is directed to a compound of formula III:
• R 1 is hydrogen, halogen, cyano, alkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, aralkyl, heteroalykl, —O-alkyl, —O-aryl, —O-heteroaryl, —S-alkyl, alkylene-O-alkyl, alkylene-CO 2 H, alkylene-CO 2 alkyl, alkylSO 2 , alkylenesulfonyl, alkylene-CO-amino, alkylene-CO-alkylamino, alkylene-CO-dialkylamino, alkylene-NH—CO 2 H, alkylene-NH—CO 2 alkyl —CO 2 alkyl, —OH, —C(O)-alkyl, —C(O)O-alkyl, —CONH 2 , —CO-alkylamino, —CO-dialkylamino, amino, alkylamino,
• A is (C 1 -C 20 )alkylene, (C 2 -C 20 )alkenylene, or (C 2 -C 20 )alkynylene, each of which may be optionally substituted on carbon with 1, 2, or 3 groups selected from OH, CO 2 H, CO 2 alkyl, halogen, amino, alkylamino, dialkylamino, —O-alkyl, alkylene-O-alkyl, alkylene-OH, or alkylene-CO 2 H;
• X 1 is a bond or is CH 2 , O, —CH 2 O—, S, —S(O), —S(O) 2 , —C(O)—, —C(O)O—, or NR x , wherein R x is H or (C 1 -C 6 )alkyl;
• R′ and R′′ are each independently hydrogen, halogen, alkyl optionally substituted on carbon with halogen, alkyl, or taken together with the carbon to which they are attached form C ⁇ O or a 3, 4, 5, or 6-membered ring, optionally containing 1 or 2 heteroatoms selected from ONH, N-alkyl, SO, or SO 2 , any of which may be optionally substituted on carbon with alkyl or halogen R 3 is absent, hydrogen, halogen, cyano, alkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, aralkyl, heteroalykl, —O-alkyl, —O-aryl, —O-heteroaryl, aralkoxy, heteroaralkoxy, —S-alkyl, alkylene-O-alkyl, alkylene-CO 2 H, alkylene-CO 2 alkyl, alkylSO 2 , alkylenesulfonyl, alkylene
• aryl, heteroaryl, heterocyclo, or cycloalkyl any of which may be optionally substituted on carbon with 1, 2, or 3 groups selected form halogen, alkyl, O-alkyl, CO 2 H, CO 2 alkyl, halogen, amino, alkylamino, dialkylamino, —O-alkyl, alkylene-O-alkyl, alkylene-OH, or alkylene-CO 2 H, provided that
• R 4 is hydrogen, cyano, alkyl, aryl, heteroaryl, alkylene-O-alkyl, alkylene-OH, aryl, alkylene-O-alkyl, —CO 2 H, —CO 2 -alkyl, alkylene-CO 2 H, or alkylene-CO 2 -alkyl, alkylene-OC(O)R wherein R is hydrogen or alkyl; cycloalkyl, heterocycloalkyl, alkylene-NH 2 , alkylene-alkylamino, or alkylene-dialkylamino, any of which may be optionally substituted on carbon with 1, 2, or 3 groups selected from OH, CO 2 H, CO 2 alkyl, halogen, amino, alkylamino, dialkylamino, —O-alkyl, alkylene-O-alkyl, alkylene-OH, or alkylene-CO 2 H;
• R 5 and R 6 are each independently selected from the group consisting of hydrogen, alkyl, alkylene-OH, aryl, alkylene-O-alkyl, —CO 2 H, CO 2 -alkyl, alkylene-OC(O)alkyl, cycloalkyl, heterocyclo, —C(O)-alkyl, —C(O)-aryl, C(O)-aralkyl, —C(O)-Oalkyl, —C(O)—Oaryl, —C(O)—Oaralkyl, alkylene-amino, alkylene-alkylamino, and alkylene-dialkylamino, any of which may be optionally substituted on carbon with halogen, alkyl, hydroxyl, CO 2 H, CO 2 alkyl or alkoxy; or
• R 5 and R 6 together with the nitrogen to which they are attached, may form a 3, 4, 5, or 6-membered saturated or unsaturated ring, optionally containing 1 or 2 additional heteroatoms selected from O, S, NH, or N-alkyl, and optionally substituted on carbon with halogen, alkyl, hydroxyl, or alkoxy;
• R 8 is hydrogen, alkyl or aryl
• n 0, 1, or 2.
• compounds of the present invention include compounds listed in the following table:
• n for each compound is 0, 1 or 2, as well as pharmaceutically acceptable salts, phosphate derivatives, phosphate mimics, or phosphate precursor analogs thereof.
• the present invention is directed to compound selected from:
• the present invention is directed to a compound which is (S)-2-Amino-2-(5-(4-(octyloxy)-3-(trifluoromethyl)phenyl)thiazol-2-yl)propan-1-ol or a pharmaceutically acceptable salt, phosphate derivative, phosphate mimic, or phosphate precursor analog thereof._In other aspects, the present invention is directed to a compound which is (S)-2-Amino-2-(5-(4-(octyloxy)-3-(trifluoromethyl)phenyl)thiazol-2-yl)propyl dihydrogen phosphate or a pharmaceutically acceptable salt thereof.
• the present invention is directed to a compound which is (S)-2-Amino-2-(5-(4-(octyloxy)-3-(trifluoromethyl)phenyl)-1,3,4-thiadiazol-2-yl)propan-1-ol or a pharmaceutically acceptable salt, phosphate derivative, phosphate mimic, or a phosphate precursor analog thereof.
• the present invention is directed to a compound which is (S)-2-Amino-2-(5-(4-(octyloxy)-3-(trifluoromethyl)phenyl)-1,3,4-thiadiazol-2-yl)propyl dihydrogen phosphate or a pharmaceutically acceptable salt thereof.
• the present invention is directed to a method of treating a sphingosine 1-phosphate associated disorder in a subject in need thereof comprising administering to the subject a therapeutically safe and effective amount of a compound of any of formulas I, II or III, or a pharmaceutically acceptable salt, phosphate derivative, phosphate mimic, or phosphate precursor analog thereof, such that the sphingosine 1-phosphate associated disorder is treated.
• the present invention is directed to a method of treating an autoimmune disorder comprising administering to a subject in need thereof a pharmaceutically acceptable amount of a compound of any of formulas I, II or III, such that the autoimmune disorder is treated.
• the present invention is directed to a method treating transplant rejection comprising administering to a subject in need thereof a pharmaceutically acceptable amount of a compound of any of formulas I, II or III, such that the transplant rejection is treated.
• the present invention is directed to a compound of any of formulas I, II or III for use as a therapeutic substance.
• the present invention is directed to a compound of any of formulas I, II or III for use in the treatment of sphingosine associated disorders. In some aspects, the present invention is directed to a compound of any of formulas I, II or III for use in the treatment of multiple sclerosis.
• the present invention is directed to a compound of any of formulas I, II or III for use in the manufacture of a medicament for use in the treatment of sphingosine associated disorders. In some aspects, the present invention is directed to a compound of any of formulas I, II or III for use in the manufacture of a medicament for the treatment of multiple sclerosis.
• the present invention is directed to a pharmaceutical composition
• a pharmaceutical composition comprising a compound of any of formulas I, II or III and a pharmaceutically acceptable carrier.
• the present invention is directed to a process for making any of the compounds described herein.
• Halogen or “halo” means fluoro (F), chloro (Cl), bromo (Br), or iodo (I).
• hydrocarbon used alone or as a suffix or prefix, refers to any structure comprising only carbon and hydrogen atoms up to 14 carbon atoms.
• hydrocarbon radical or “hydrocarbyl” used alone or as a suffix or prefix, refers to any structure as a result of removing one or more hydrogens from a hydrocarbon.
• alkyl used alone or as a suffix or prefix, refers to monovalent straight or branched chain hydrocarbon radicals comprising 1 to about 12 carbon atoms.
• alkylene used alone or as suffix or prefix, refers to divalent straight or branched chain hydrocarbon radicals comprising 1 to about 12 carbon atoms, which serves to links two structures together.
• cycloalkyl used alone or as suffix or prefix, refers to a saturated or partially unsaturated monovalent ring-containing hydrocarbon radical comprising at least 3 up to about 12 carbon atoms.
• aryl used alone or as suffix or prefix, refers to a monovalent hydrocarbon radical having one or more polyunsaturated carbon rings having aromatic character, and comprising 5 up to about 14 carbon atoms.
• heterocycle used alone or as a suffix or prefix, refers to a ring-containing structure or molecule having one or more multivalent heteroatoms, independently selected from N, O and S, as a part of the ring structure and including at least 3 and up to about 20 atoms in the ring(s).
• Heterocycle may be saturated or unsaturated, containing one or more double bonds, and heterocycle may contain more than one ring.
• the rings may be fused or unfused.
• Fused rings generally refer to at least two rings share two atoms therebetween.
• Heterocycle may have aromatic character or may not have aromatic character.
• heterocyclic group refers to a radical derived from a heterocycle by removing one or more hydrogens therefrom.
• heterocyclyl used alone or as a suffix or prefix, refers a monovalent radical derived from a heterocycle by removing one hydrogen therefrom.
• heteroaryl used alone or as a suffix or prefix, refers to a heterocyclyl having aromatic character.
• Heterocycle includes, for example, monocyclic heterocycles such as: aziridine, oxirane, thiirane, azetidine, oxetane, thietane, pyrrolidine, pyrroline, imidazolidine, pyrazolidine, pyrazoline, dioxolane, sulfolane 2,3-dihydrofuran, 2,5-dihydrofuran tetrahydrofuran, thiophane, piperidine, 1,2,3,6-tetrahydro-pyridine, piperazine, morpholine, thiomorpholine, pyran, thiopyran, 2,3-dihydropyran, tetrahydropyran, 1,4-dihydropyridine, 1,4-dioxane, 1,3-dioxane, dioxane, homopiperidine, 2,3,4,7-tetrahydro-1H-azepine homopiperazine, 1,
• heterocycle includes aromatic heterocycles (heteroaryl groups), for example, pyridine, pyrazine, pyrimidine, pyridazine, thiophene, furan, furazan, pyrrole, imidazole, thiazole, oxazole, pyrazole, isothiazole, isoxazole, 1,2,3-triazole, tetrazole, 1,2,3-thiadiazole, 1,2,3-oxadiazole, 1,2,4-triazole, 1,2,4-thiadiazole, 1,2,4-oxadiazole, 1,3,4-triazole, 1,3,4-thiadiazole, and 1,3,4-oxadiazole.
• aromatic heterocycles heteroaryl groups
• heterocycle encompass polycyclic heterocycles, for example, indole, indoline, isoindoline, quinoline, tetrahydroquinoline, isoquinoline, tetrahydroisoquinoline, 1,4-benzodioxan, coumarin, dihydrocoumarin, benzofuran, 2,3-dihydrobenzofuran, isobenzofuran, chromene, chroman, isochroman, xanthene, phenoxathiin, thianthrene, indolizine, isoindole, indazole, purine, phthalazine, naphthyridine, quinoxaline, quinazoline, cinnoline, pteridine, phenanthridine, perimidine, phenanthroline, phenazine, phenothiazine, phenoxazine, 1,2-benzisoxazole, benzothiophene, benzoxazole
• heterocycle includes polycyclic heterocycles wherein the ring fusion between two or more rings includes more than one bond common to both rings and more than two atoms common to both rings.
• bridged heterocycles include quinuclidine, diazabicyclo[2.2.1]heptane and 7-oxabicyclo[2.2.1]heptane.
• Heterocyclyl includes, for example, monocyclic heterocyclyls, such as: aziridinyl, oxiranyl, thiiranyl, azetidinyl, oxetanyl, thietanyl, pyrrolidinyl, pyrrolinyl, imidazolidinyl, pyrazolidinyl, pyrazolinyl, dioxolanyl, sulfolanyl, 2,3-dihydrofuranyl, 2,5-dihydrofuranyl, tetrahydrofuranyl, thiophanyl, piperidinyl, 1,2,3,6-tetrahydro-pyridinyl, piperazinyl, morpholinyl, thiomorpholinyl, pyranyl, thiopyranyl, 2,3-dihydropyranyl, tetrahydropyranyl, 1,4-dihydropyridinyl, 1,4-di
• heterocyclyl includes aromatic heterocyclyls or heteroaryl, for example, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, thienyl, furyl, furazanyl, pyrrolyl, imidazolyl, thiazolyl, oxazolyl, pyrazolyl, isothiazolyl, isoxazolyl, 1,2,3-triazolyl, tetrazolyl, 1,2,3-thiadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-triazolyl, 1,2,4-thiadiazolyl, 1,2,4-oxadiazolyl, 1,3,4-triazolyl, 1,3,4-thiadiazolyl, and 1,3,4 oxadiazolyl.
• heterocyclyl encompasses polycyclic heterocyclyls (including both aromatic or non-aromatic), for example, indolyl, indolinyl, isoindolinyl, quinolinyl, tetrahydroquinolinyl, isoquinolinyl, tetrahydroisoquinolinyl, 1,4-benzodioxanyl, coumarinyl, dihydrocoumarinyl, benzofuranyl, 2,3-dihydrobenzofuranyl, isobenzofuranyl, chromenyl, chromanyl, isochromanyl, xanthenyl, phenoxathiinyl, thianthrenyl, indolizinyl, isoindolyl, indazolyl, purinyl, phthalazinyl, naphthyridinyl, quinoxalinyl, quinazolinyl, cinnolinyl, pteri
• heterocyclyl includes polycyclic heterocyclyls wherein the ring fusion between two or more rings includes more than one bond common to both rings and more than two atoms common to both rings.
• bridged heterocycles include quinuclidinyl, diazabicyclo[2.2.1]heptyl; and 7-oxabicyclo[2.2.1]heptyl.
• five-membered used as prefix refers to a group having a ring that contains five ring atoms.
• a five-membered heteroaryl ring is a heteroaryl with a ring having five ring atoms wherein 1, 2 or 3 ring atoms are independently selected from N, O and S.
• Exemplary five-membered ring heteroaryls are thienyl, furyl, pyrrolyl, imidazolyl, thiazolyl, oxazolyl, pyrazolyl, isothiazolyl, isoxazolyl, 1,2,3-triazolyl, tetrazolyl, 1,2,3-thiadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-triazolyl, 1,2,4-thiadiazolyl, 1,2,4-oxadiazolyl, 1,3,4-triazolyl, 1,3,4-thiadiazolyl, and 1,3,4-oxadiazolyl.
• a six-membered ring heteroaryl is a heteroaryl with a ring having six ring atoms wherein 1, 2 or 3 ring atoms are independently selected from N, O and S.
• Exemplary six-membered ring heteroaryls are pyridyl, pyrazinyl, pyrimidinyl, triazinyl and pyridazinyl.
• aralkyl refers to an alkyl group substituted with an aryl group.
• heteroarylkyl refers to an alkyl group substituted with an heteroaryl group.
• substituted when used as a prefix, refers to a structure, molecule or group, wherein one or more hydrogens are replaced with one or more alkyl groups, or one or more chemical groups containing one or more heteroatoms selected from N, O, S, F, Cl, Br, I, and P.
• Exemplary chemical groups containing one or more heteroatoms include heterocyclyl, —NO 2 , —O-alkyl, halo, —CF 3 , —CO 2 H, —CO 2 R, —NH 2 , —SH, —NHR, —NR 2 , —SR, —SO 3 H, —SO 2 R, —S(O)R, —CN, —OH, —C(O)NR 2 , —NRC(O)R, oxo ( ⁇ O), imino ( ⁇ NR), thio ( ⁇ S), and oximino ( ⁇ N—OR), wherein each “R” is alkyl as defined above.
• substituted phenyl may refer to nitrophenyl, pyridylphenyl, methoxyphenyl, chlorophenyl, aminophenyl, an so on, wherein the nitro, pyridyl, methoxy, chloro, and amino groups may replace any suitable hydrogen on the phenyl ring.
• substitution or “substituted with” includes the implicit proviso that such substitution is in accordance with the permitted valence of the substituted atom and the substituent, and that the substitution results in a stable compound, e.g., which does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, etc.
• alkoxy used alone or as a suffix or prefix, refers to radicals of the general —O-alkyl
• Exemplary alkoxy groups includes methoxy, ethoxy, propoxy, isopropoxy, butoxy, t-butoxy, isobutoxy, cyclopropylmethoxy, allyloxy, and propargyloxy.
• amine or “amino” used alone or as a suffix or prefix, refers —NH 2 .
• alkylamino used alone or as a suffix or prefix, refers —NH(alkyl).
• dialkylamino used alone or as a suffix or prefix, refers —NH(alkyl) 2 .
• Acyl used alone, as a prefix or suffix, means —C(O)—R, wherein R hydrogen, hydroxyl, amino, alkylamino, dialkylamino, or alkoxy, any of which may be substituted as provided by the definition of “substituted” given above.
• Acyl groups include, for example, acetyl, propionyl, benzoyl, phenyl acetyl, carboethoxy, and dimethylcarbamoyl.
• Some of the compounds in the present invention may exist as stereoisomers, including enantiomers, diastereomers, and geometric isomers. All of these forms, including (R), (S), epimers, diastereomers, cis, trans, syn, anti, solvates (including hydrates), tautomers, and mixtures thereof, are contemplated in the compounds of the present invention.
• the invention also relates to salts of the compounds of the invention and, in particular, to pharmaceutically acceptable salts.
• a “pharmaceutically acceptable salt” is a salt that retains the desired biological activity of the parent compound and does not impart any undesired toxicological effects.
• the salts can be, for example, salts with a suitable acid, such as hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, and the like; acetic acid, oxalic acid, tartaric acid, succinic acid, malic acid, benzoic acid, pamoic acid, alginic acid, methanesulfonic acid, naphthalenesulfonic acid, and the like.
• salts of cations such as ammonium, sodium, potassium, lithium, zinc, copper, barium, bismuth, calcium, and the like; or organic cations such as tetralkylammonium and trialkylammonium cations. Combinations of the above salts are also useful. Salts of other acids and/or cations are also included, such as salts with trifluoroacetic acid, chloroacetic acid, and trichloroacetic acid.
• the invention also includes different crystal forms, hydrates, and solvates of the compounds of the invention.
• phosphate precursor and “phosphate precursor analog,” as used herein, refer to substituent moieties in invention compounds that may be directly phosphorylated in vivo, or which may be cleaved in vivo to reveal a moiety that may then be phosphorylated in vivo.
• the phosphate precursor may be L 1 -O—H or L 1 -O-L 2 , wherein L 1 is a linking moiety and L 2 is a labile moiety.
• Exemplary embodiments of the phosphate precursor include but are not limited to -alkyl-OH, -halo-alkyl-OH, alkoxy-OH, -alkyl-OCOR a , -halo-alkyl-OCOR a , -alkoxy-OCOR a , -alkyl-OC(O)NR a R b , -halo-alkyl-OC(O)NHR a R b , -alkoxy-OC(O)NR a R b , —(CH 2 ) q CO 2 R c , and —(CH 2 ) n CH 2 ⁇ CHC(O)OR c , wherein
• q is an integer between 0 and 4.
• R a and R b are independently selected from the group consisting of hydrogen, straight chain or branched C 1 -C 6 -alkyl, all of which may be optionally substituted with OH, halogen, straight chain or branched C 1 -C 6 -alkoxy, straight chain or branched halo-C 1 -C 6 -alkyl, straight chain or branched halo-C 1 -C 6 -alkoxy, C 1 -C 6 -alkoxy-C 1 -C 6 -alkyl, hydroxyl-C 1 -C 6 -alkyl, carboxy-C 1 -C 6 -alkyl, substituted or unsubstituted C 3 -C 10 carbocyclic rings, and substituted or unsubstituted C 3 -C 10 heterocyclic rings, which may contain one or more heteroatoms and may be saturated or unsaturated; and
• R c is selected from the group consisting of hydrogen, straight chain or branched C 1 -C 6 -alkyl, straight chain or branched halo-C 1 -C 6 -alkyl, substituted or unsubstituted aryl group, or one of the following groups.
• the “linking moiety,” may contain 1-8 atoms or may be a bond, and serves as the connection point through which the phosphate mimic, phosphate derivative, or phosphate precursor substituent moieties are linked to the remaining structure of the compounds of the invention.
• the linking moiety may include, but is not limited to, substituted or unsubstituted alkyl (e.g., methylene chains), substituted or unsubstituted alkenyl (e.g., n-alkenes), substituted or unsubstituted alkynyl, substituted or unsubstituted halo-alkyl, substituted or unsubstituted alkoxy, and substituted or unsubstituted halo-alkoxy.
• the linking moiety may be carbonyl derivatized.
• labile moiety refers to a moiety that is subject to cleavage, for instance, by hydrolysis or enzymatic degradation.
• the labile moiety is an ester moiety, which may result in a carboxylate or hydroxyl derivative, depending on the orientation of the ester functionality in the molecule prior to cleavage.
• phosphate derivative refers to substituent moieties in invention compounds that contain a phosphate or phosphate ester group.
• the compound may act as is in vivo or the phosphate derivative (within the compound) may be cleaved and then re-phosphorylated in vivo leading to an active compound.
• the phosphate derivative may be selected from the group consisting of —(CH 2 ) q OPO 2 R d R e , —(CH 2 ) q OPO 3 R d R e , and —(CH 2 ) q OPO 2 (S)R d R e , wherein
• q is an integer between 0 and 4.
• R d and R e are each independently selected from the group consisting of hydrogen, straight chain or branched C 1 -C 6 -alkyl, straight chain or branched halo-C 1 -C 6 -alkyl, substituted or unsubstituted aryl group, and a prodrug derivatizing moiety (PDM).
• PDM prodrug derivatizing moiety
• phosphate mimic refers to substituent moieties in invention compounds in which a phosphate substrate has been replaced with a non-hydrolyzable functional group, resulting in a moiety that mimics the biological function of a phosphate or phosphate ester moiety.
• the phosphate mimic is -L 1 -Z 2 , wherein L 1 is a linking moiety and Z 2 is a non-hydrolyzable moiety covalently bonded, to L 1 .
• the phosphate mimic is selected from the group consisting of —(CH 2 ) q CH 2 PO 3 R d R e , and —(CH 2 ) q C(Y 1 )(Y 2 )PO 3 R d R e , wherein
• q is an integer between 0 and 4.
• Y 1 and Y 2 are independently selected from the group consisting of hydrogen, straight chain or branched C 1 -C 6 -alkyl, all of which may be optionally substituted with OH, halogen, straight chain or branched C 1 -C 6 -alkoxy, straight chain or branched halo-C 1 -C 6 -alkyl, straight chain or branched halo-C 1 -C 6 -alkoxy, C 1 -C 6 -alkoxy-C 1 -C 6 -alkyl, hydroxyl-C 1 -C 6 -alkyl, carboxy-C 1 -C 6 -alkyl, substituted or unsubstituted C 3 -C 10 carbocyclic rings, and substituted or unsubstituted C 3 -C 10 heterocyclic rings, which may contain one or more heteroatoms and may be saturated or unsaturated; and
• R d and R e are each independently selected from the group consisting of hydrogen, straight chain or branched C 1 -C 6 -alkyl, straight chain or branched halo-C 1 -C 6 -alkyl, substituted or unsubstituted aryl group, and a prodrug derivatizing moiety (PDM).
• PDM prodrug derivatizing moiety
• non-hydrolyzable moiety refers to moieties containing bonds, such as carbon-phosphorous bonds, that are not hydrolyzable in vivo.
• the present invention is directed to a compound of formula I:
• R 1 is hydrogen, halogen, cyano, alkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, aralkyl, heteroalykl, —O-alkyl, —O-aryl, —O-heteroaryl, —S-alkyl, alkylene-O-alkyl, alkylene-CO 2 H, alkylene-CO 2 alkyl, alkylSO 2 , alkylenesulfonyl, alkylene-CO-amino, alkylene-CO-alkylamino, alkylene-CO-dialkylamino, alkylene-NH—CO 2 H, alkylene-NH—CO 2 alkyl —CO 2 alkyl, —OH, —C(O)-alkyl, —C(O)O-alkyl, —CONH 2 , —CO-alkylamino, —CO-dialkylamino, amino, alkylamino,
• A is (C 1 -C 20 )alkylene, (C 2 -C 20 )alkenylene, or (C 2 -C 20 )alkynylene, each of which may be optionally substituted on carbon with 1, 2, or 3 groups selected from OH, CO 2 H, CO 2 alkyl, halogen, amino, alkylamino, dialkylamino, —O-alkyl, alkylene-O-alkyl, alkylene-OH, or alkylene-CO 2 H;
• X 1 is a bond or is CH 2 , O, —CH 2 O—, S, —S(O), —S(O) 2 , —C(O)—, —C(O)O—, or NR x , wherein R x is H or (C 1 -C 6 )alkyl;
• R′ and R′′ are each independently hydrogen, halogen, alkyl optionally substituted on carbon with halogen, alkyl, or taken together with the carbon to which they are attached form C ⁇ O or a 3, 4, 5, or 6-membered ring, optionally containing 1 or 2 heteroatoms selected from ONH, N-alkyl, SO, or SO 2 , any of which may be optionally substituted on carbon with alkyl or halogen
• R 2 is cyano, alkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, aralkyl, heteroalykl, —O-alkyl, —O-aryl, —O-heteroaryl, aralkoxy, heteroaralkoxy, —S-alkyl, alkylene-O-alkyl, alkylene-CO 2 H, alkylene-CO 2 alkyl, alkylSO 2 , alkylenesulfonyl, alkylene-CO-amino
• R 3 is absent, hydrogen, halogen, cyano, alkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, aralkyl, heteroalykl, —O-alkyl, —O-aryl, —O-heteroaryl, aralkoxy, heteroaralkoxy, —S-alkyl, alkylene-O-alkyl, alkylene-CO 2 H, alkylene-CO 2 alkyl, alkylSO 2 , alkylenesulfonyl, alkylene-CO-amino, alkylene-CO-alkylamino, alkylene-CO-dialkylamino, alkylene-NH—CO 2 H, alkylene-NH—CO 2 alkyl —CO 2 alkyl, —OH, —C(O)-alkyl, —C(O)O-alkyl, —CONH 2 , —CO-alkylamino, —CO-
• aryl, heteroaryl, heterocyclo, or cycloalkyl any of which may be optionally substituted on carbon with 1, 2, or 3 groups selected form halogen, alkyl, O-alkyl, CO 2 H, CO 2 alkyl, halogen, amino, alkylamino, dialkylamino, —O-alkyl, alkylene-O-alkyl, alkylene-OH, or alkylene-CO 2 H, provided that
• R 4 is hydrogen, cyano, alkyl, aryl, heteroaryl, alkylene-O-alkyl, alkylene-OH, aryl, alkylene-O-alkyl, —CO 2 H, —CO 2 -alkyl, alkylene-CO 2 H, or alkylene-CO 2 -alkyl, alkylene-OC(O)R wherein R is hydrogen or alkyl; cycloalkyl, heterocycloalkyl, alkylene-NH 2 , alkylene-alkylamino, or alkylene-dialkylamino, any of which may be optionally substituted on carbon with 1, 2, or 3 groups selected from OH, CO 2 H, CO 2 alkyl, halogen, amino, alkylamino, dialkylamino, —O-alkyl, alkylene-O-alkyl, alkylene-OH, or alkylene-CO 2 H;
• R 5 and R 6 are each independently selected from the group consisting of hydrogen, alkyl, alkylene-OH, aryl, alkylene-O-alkyl, —CO 2 H, CO 2 -alkyl, alkylene-OC(O)alkyl, cycloalkyl, heterocyclo, —C(O)-alkyl, —C(O)-aryl, C(O)-aralkyl, —C(O)-Oalkyl, —C(O)—Oaryl, —C(O)—Oaralkyl, alkylene-amino, alkylene-alkylamino, and alkylene-dialkylamino, any of which may be optionally substituted on carbon with halogen, alkyl, hydroxyl, CO 2 H, CO 2 alkyl or alkoxy; or
• R 5 and R 6 together with the nitrogen to which they are attached, may form a 3, 4, 5, or 6-membered saturated or unsaturated ring, optionally containing 1 or 2 additional heteroatoms selected from O, S, NH, or N-alkyl, and optionally substituted on carbon with halogen, alkyl, hydroxyl, or alkoxy;
• R 7 is selected from the group consisting of —OH, —O-alkyl, alkylene-OH, —CO 2 H, alkylene-CO 2 H, —C(O)O-alkyl, -alkylene-CO 2 -alkyl, —C(O)O-aryl, —CH 2 ⁇ CHCO 2 H, —CH 2 ⁇ CHC(O)O-alkyl, —CH 2 ⁇ CHC(O)O-aryl, —OPO 2 R p1 R p2 , —OPO 3 R p1 R p2 , —CH 2 PO 3 R p1 R p2 , —OPO 2 (S)R p1 R p2 , and —C(Z′)(Z′′)PO 3 R p1 R p2 , any of which may be optionally substituted on carbon with halogen, alkyl, hydroxyl, carboxy, or alkoxy; and wherein
• Z′ is hydroxyl or halogen
• Z′′ is H or halogen
• R p1 and R p2 are each independently hydrogen, C 1 -C 6 -alkyl, aryl, or one of the following groups:
• Y is heterocyclo or heteroaryl.
• R 1 is aryl or heteroaryl, optionally substituted with 1, 2, or 3 groups selected from halo, alkyl, haloalkyl, -aryl, —CF 3 , —CN, —OH, or —O-alkyl.
• R 1 is aryl, e.g., phenyl, optionally substituted with 1 or 2 groups selected from —CF 3 , —CN, —OMe, —Cl or —F.
• R 1 is heteroaryl, e.g., thiophene or benzothiophene, optionally substituted with 1 or 2 groups selected from phenyl, —CF 3 , —CN, —OMe, —Cl or —F.
• R 1 is hydrogen.
• R 1 is phenyl.
• R 1 is pyridyl.
• R 1 is thiophenyl.
• R 1 is cyclohexyl.
• R 1 is cyclopentyl.
• A is a C 1 -C 10 alkylene. In some embodiments, A is a branched C 1 -C 10 alkylene. In other embodiments, A is n-octyl. In other embodiments, A is n-heptyl. In other embodiments, A is n-hexyl. In some embodiments, A is a C 1 -C 5 alkylene. In some embodiments, A is n-pentyl. In other embodiments, A is n-butyl. In still other embodiments, A is n-propyl. In other embodiments, A is ethyl. In still other embodiments, A is methyl.
• X 1 is O. In other embodiments, X 1 is S. In still other embodiments, X 1 is SO 2 . In some embodiments, X 1 is CH 2 . In other embodiments, X 1 is C ⁇ O. In still other embodiments, CH 2 O, wherein either the oxygen or the carbon may be attached to
• R′ is hydrogen. In other embodiments, R′ is methyl. In some embodiments, R′′ is hydrogen. In other embodiments, R′ is methyl. In some embodiments, R′ and R′′ taken together with the carbon to which they are attached, is C ⁇ O, with the provision that only one of X 1 or R′ and R′′ taken together with the carbon may form C ⁇ O.
• the compounds of the present invention include a selectivity enhancing moiety.
• selectivity enhancing moiety SEM is defined in U.S. application Ser. No. 11/349,069 filed on Feb. 6, 2006 which is assigned to the assignee of the present application, the contents of which are incorporated herein by reference, refers to one or more moieties that provide an enhancement in the selectivity of the compound to which they are attached for the S1P-1 receptor, as compared to the compound not containing the moiety or moieties.
• the SEM confers selectivity to the compound to which it is attached for the S1P-1 receptor as compared to, for example, the S1P-2 to S1P-5 receptors.
• the enhancement conferred to a compound by the SEM may be measured by, for example, determining the binding specificity of a compound for the S1P-1 receptor and one or more of the other S1P receptors wherein enhancement conferred to a compound by the SEM may be in the form of increased potency.
• at least one of R 2 and/or R 3 is an SEM.
• the SEM is a halo-substituted alkyl group such as CF 3 , CF 2 CF 3 , CF 2 CF 2 CF 3 , CFHCF 3 , CH 2 CF 3 , CH 2 CH 2 CF 3 , CHCl 2 , or CH 2 Cl.
• the SEM may possess a selectivity enhancing orientation (SEQ).
• SEQ selectivity enhancing orientation
• SEQ selectivity enhancing orientation
• U.S. application Ser. No. 11/349,069 filed on Feb. 6, 2006 which is assigned to the assignee of the present application, the contents of which are incorporated herein by reference and as used herein refers to the relative selectivity enhancement of a compound based on the orientation of the SEM as well as the additional substitutents on the ring, either alone or in combination with each other.
• the SEQ may result from the orientation of the SEM on the ring to which it is attached, in relation to any other ring and/or moiety attached to the same ring.
• the SEM is in the meta position relative to X 1 .
• R 2 is alkyl substituted with 1, 2 or 3 halo groups. In some embodiments, R 2 is trifluoromethyl. In still other embodiments, R 2 is methyl.
• R 3 is absent.
• R 3 is absent.
• R 3 would be considered absent, because there no substituents on the ring. In other embodiments, R 3 is halogen.
• R 4 is hydrogen. In other embodiments, R 4 is an alkyl, e.g., a C 1 -C 4 alkyl. For example, in some embodiments, R 4 is methyl. In some embodiments, R 4 is hydroxymethyl.
• R 5 is hydrogen. In some embodiments, R 6 is hydrogen. In some embodiments, R 5 is an alkyl, e.g., a C 1 -C 4 alkyl. In some embodiments, R 6 is an alkyl, e.g., a C 1 -C 4 alkyl.
• R 7 is OH. In other embodiments, R 7 is CO 2 H. In still other embodiments, R 7 is CO 2 Me or CO 2 Et. In other embodiments, R 7 is CO 2 -phenyl. In still other embodiments, R 7 is —OP(O) 3 H 2 . In other embodiments, R 7 is —CH 2 P(O) 3 H 2 .
• R can be hydrogen or alkyl.
• compounds of the invention are compounds wherein
• R 1 is hydrogen, aryl, cycloalkyl, or heteroaryl.
• R 4 is hydrogen, alkyl, alkylene-OH, aryl, -alkylene-O-alkyl, alkylene-CO 2 H, or -alkylene-CO 2 -alkyl;
• R 5 and R 6 are each independently hydrogen or alkyl, or alkylene-OH;
• R 7 is selected from the group consisting of OH, alkylene-OH, —CO 2 H, alkylene-CO 2 H,
• -alkylene-CO 2 -alkyl C(O)O-alkyl, —C(O)O-aryl, —CH 2 ⁇ CHCO 2 H, —CH 2 ⁇ CHC(O)O-alkyl, —CH 2 ⁇ CHC(O)O-aryl, —OPO 2 R p1 R p2 , —OPO 3 R p1 R p2 , —CH 2 PO 3 R p1 R p2 , —OPO 2 (S)R p1 R p2 , or
• compounds of the invention are compounds wherein
• R 1 is hydrogen or aryl
• R 4 is hydrogen or alkyl
• R 5 and R 6 are each independently hydrogen or alkyl, or alkylene-OH;
• R 7 is selected from the group consisting of —OH, alkylene-OH, —CO 2 H, alkylene-CO 2 H,
• compounds of the invention are compounds wherein
• R 1 is phenyl
• A is (C 1 -C 10 )alkyl
• R′ and R′′ are hydrogen
• X 1 is O
• R 4 is hydrogen, alkyl, or alkylene-OH
• R 5 and R 6 are each independently hydrogen, alkyl
• R 7 is selected from the group consisting of —OH, alkylene-OH, —CO 2 H, alkylene-CO 2 H,
• compounds of the invention are compounds of formula I-1.
• Another specific group of compounds of the invention are compounds of formula I-2.
• the present invention is directed to a compound of formula II:
• R 1 is hydrogen, halogen, cyano, alkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, aralkyl, heteroalykl, —O-alkyl, —O-aryl, —O-heteroaryl, —S-alkyl, alkylene-O-alkyl, alkylene-CO 2 H, alkylene-CO 2 alkyl, alkylSO 2 , alkylenesulfonyl, alkylene-CO-amino, alkylene-CO-alkylamino, alkylene-CO-dialkylamino, alkylene-NH—CO 2 H, alkylene-NH—CO 2 alkyl —CO 2 alkyl, —OH, —C(O)-alkyl, —C(O)O-alkyl, —CONH 2 , —CO-alkylamino, —CO-dialkylamino, amino, alkylamino,
• A is (C 1 -C 20 )alkylene, (C 2 -C 20 )alkenylene, or (C 2 -C 20 )alkynylene, each of which may be optionally substituted on carbon with 1, 2, or 3 groups selected from OH, CO 2 H, CO 2 alkyl, halogen, amino, alkylamino, dialkylamino, —O-alkyl, alkylene-O-alkyl, alkylene-OH, or alkylene-CO 2 H;
• X 1 is a bond or is CH 2 , O, —CH 2 O—, S, —S(O), —S(O) 2 , —C(O)—, —C(O)O—, or NR x , wherein R x is H or (C 1 -C 6 )alkyl;
• R′ and R′′ are each independently hydrogen, halogen, alkyl optionally substituted on carbon with halogen, alkyl, or taken together with the carbon to which they are attached form C ⁇ O or a 3, 4, 5, or 6-membered ring, optionally containing 1 or 2 heteroatoms selected from ONH, N-alkyl, SO, or SO 2 , any of which may be optionally substituted on carbon with alkyl or halogen
• R 3 is absent, hydrogen, halogen, cyano, alkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, aralkyl, heteroalykl, —O-alkyl, —O-aryl, —O-heteroaryl, aralkoxy, heteroaralkoxy, —S-alkyl, alkylene-O-alkyl, alkylene-CO 2 H, alkylene-CO 2 alkyl, alkylSO 2 , alkylenesulfonyl, alkylene-CO-amino, alkylene-CO-alkylamino, alkylene-CO-dialkylamino, alkylene-NH—CO 2 H, alkylene-NH—CO 2 alkyl —CO 2 alkyl, —OH, —C(O)-alkyl, —C(O)O-alkyl, —CONH 2 , —CO-alkylamino,
• aryl, heteroaryl, heterocyclo, or cycloalkyl any of which may be optionally substituted on carbon with 1, 2, or 3 groups selected form halogen, alkyl, O-alkyl, CO 2 H, CO 2 alkyl, halogen, amino, alkylamino, dialkylamino, —O-alkyl, alkylene-O-alkyl, alkylene-OH, or alkylene-CO 2 H, provided that
• R 4 is hydrogen, cyano, alkyl, aryl, heteroaryl, alkylene-O-alkyl, alkylene-OH, aryl, alkylene-O-alkyl, —CO 2 H, —CO 2 -alkyl, alkylene-CO 2 H, or alkylene-CO 2 -alkyl, alkylene-OC(O)R wherein R is hydrogen or alkyl; cycloalkyl, heterocycloalkyl, alkylene-NH 2 , alkylene-alkylamino, or alkylene-dialkylamino, any of which may be optionally substituted on carbon with 1, 2, or 3 groups selected from OH, CO 2 H, CO 2 alkyl, halogen, amino, alkylamino, dialkylamino, —O-alkyl, alkylene-O-alkyl, alkylene-OH, or alkylene-CO 2 H;
• R 5 and R 6 are each independently selected from the group consisting of hydrogen, alkyl, alkylene-OH, aryl, alkylene-O-alkyl, —CO 2 H, CO 2 -alkyl, alkylene-OC(O)alkyl, cycloalkyl, heterocyclo, —C(O)-alkyl, —C(O)-aryl, C(O)-aralkyl, —C(O)-Oalkyl, —C(O)—Oaryl, —C(O)—Oaralkyl, alkylene-amino, alkylene-alkylamino, and alkylene-dialkylamino, any of which may be optionally substituted on carbon with halogen, alkyl, hydroxyl, CO 2 H, CO 2 alkyl or alkoxy; or
• R 5 and R 6 together with the nitrogen to which they are attached, may form a 3, 4, 5, or 6-membered saturated or unsaturated ring, optionally containing 1 or 2 additional heteroatoms selected from O, S, NH, or N-alkyl, and optionally substituted on carbon with halogen, alkyl, hydroxyl, or alkoxy;
• R 7 is selected from the group consisting of —OH, —O-alkyl, -alkylene-OH, —CO 2 H, -alkylene-CO 2 H, —C(O)O-alkyl, -alkylene-CO 2 -alkyl, —C(O)O-aryl, —CH 2 ⁇ CHCO 2 H, —CH 2 ⁇ CHC(O)O-alkyl, —CH 2 ⁇ CHC(O)O-aryl, —OPO 2 R p1 R p2 , —OPO 3 R p1 R p2 , —CH 2 PO 3 R p1 R p2 , —OPO 2 (S) R p1 R p2 , and —C(Z′)(Z′′)PO 3 R p1 R p2 , any of which may be optionally substituted on carbon with halogen, alkyl, hydroxyl, carboxy, or alkoxy; and wherein
• Z′ is hydroxyl or halogen
• Z′′ is H or halogen
• R p1 and R p2 are each independently hydrogen, C 1 -C 6 -alkyl, aryl, or one of the following groups:
• Y is heterocyclo or heteroaryl.
• R 1 is aryl or heteroaryl, optionally substituted with 1, 2, or 3 groups selected from halo, alkyl, haloalkyl, -aryl, —CF 3 , —CN, —OH, or —O-alkyl.
• R 1 is aryl, e.g., phenyl, optionally substituted with 1 or 2 groups selected from —CF 3 , —CN, —OMe, —Cl or —F.
• R 1 is heteroaryl, e.g., thiophene or benzothiophene, optionally substituted with 1 or 2 groups selected from phenyl, —CF 3 , —CN, —OMe, —Cl or —F.
• R 1 is hydrogen.
• R 1 is phenyl.
• R 1 is pyridyl.
• R 1 is thiophenyl.
• R 1 is cyclohexyl.
• R 1 is cyclopentyl.
• A is a C 1 -C 10 alkylene. In some embodiments, A is a branched C 1 -C 10 alkylene. In other embodiments, A is n-octyl. In other embodiments, A is n-heptyl. In other embodiments, A is n-hexyl. In some embodiments, A is a C 1 -C 5 alkylene. In some embodiments, A is n-pentyl. In other embodiments, A is n-butyl. In still other embodiments, A is n-propyl. In other embodiments, A is ethyl. In still other embodiments, A is methyl.
• X 1 is O. In other embodiments, X 1 is S. In still other embodiments, X 1 is SO 2 . In some embodiments, X 1 is CH 2 . In other embodiments, X 1 is C ⁇ O. In still other embodiments, CH 2 O, wherein either the oxygen or the carbon may be attached to
• R′ is hydrogen. In other embodiments, R′ is methyl. In some embodiments, R′′ is hydrogen. In other embodiments, R′′ is methyl. In some embodiments, R′ and R′′ taken together with the carbon to which they are attached, is C ⁇ O, with the provision that only one of X 1 or R′ and R′′ taken together with the carbon may form C ⁇ O.
• R 3 is absent.
• R 3 is absent.
• R 3 would be considered absent, because there no substituents on the ring. In other embodiments, R 3 is halogen.
• R 4 is hydrogen. In other embodiments, R 4 is an alkyl, e.g., a C 1 -C 4 alkyl. For example, in some embodiments, R 4 is methyl. In some embodiments, R 4 is hydroxymethyl.
• R 5 is hydrogen. In some embodiments, R 6 is hydrogen. In some embodiments, R 5 is an alkyl, e.g., a C 1 -C 4 alkyl. In some embodiments, R 6 is an alkyl, e.g., a C 1 -C 4 alkyl.
• R 7 is OH. In other embodiments, R 7 is CO 2 H. In still other embodiments, R 7 is CO 2 Me or CO 2 Et. In other embodiments, R 7 is CO 2 -phenyl. In still other embodiments, R 7 is —OP(O) 3 H 2 . In other embodiments, R 7 is —CH 2 P(O) 3 H 2 .
• R can be hydrogen or alkyl.
• compounds of formula II are compounds of formula II-1.
• heteroaryl ring containing up to four heteroatoms selected from N, O, or S, optionally substituted on carbon with halogen or alkyl, wherein
• Y 1 is CH, N, S, or O;
• Y 2 and Y 3 are each independently CH; N, O, or S; provided that when
• Y 4 is C or N.
• compounds of formula II are compounds of formula II-2.
• compounds of formula II are compounds of formula II-3.
• compounds of formula II are compounds of formula II-4.
• compounds of the present invention include compounds listed in the following table:
• the present invention is directed to a compound of formula III:
• R 1 is hydrogen, halogen, cyano, alkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, aralkyl, heteroalykl, —O-alkyl, —O-aryl, —O-heteroaryl, —S-alkyl, alkylene-O-alkyl, alkylene-CO 2 H, alkylene-CO 2 alkyl, alkylSO 2 , alkylenesulfonyl, alkylene-CO-amino, alkylene-CO-alkylamino, alkylene-CO-dialkylamino, alkylene-NH—CO 2 H, alkylene-NH—CO 2 alkyl —CO 2 alkyl, —OH, —C(O)-alkyl, —C(O)O-alkyl, —CONH 2 , —CO-alkylamino, —CO-dialkylamino, amino, alkylamino,
• A is (C 1 -C 20 )alkylene, (C 2 -C 20 )alkenylene, or (C 2 -C 20 )alkynylene, each of which may be optionally substituted on carbon with 1, 2, or 3 groups selected from OH, CO 2 H, CO 2 alkyl, halogen, amino, alkylamino, dialkylamino, —O-alkyl, alkylene-O-alkyl, alkylene-OH, or alkylene-CO 2 H;
• X 1 is a bond or is CH 2 , O, —CH 2 O—, S, —S(O), —S(O) 2 , —C(O)—, —C(O)O—, or NR x , wherein R x is H or (C 1 -C 6 )alkyl;
• R′ and R′′ are each independently hydrogen, halogen, alkyl optionally substituted on carbon with halogen, alkyl, or taken together with the carbon to which they are attached form C ⁇ O or a 3, 4, 5, or 6-membered ring, optionally containing 1 or 2 heteroatoms selected from ONH, N-alkyl, SO, or SO 2 , any of which may be optionally substituted on carbon with alkyl or halogen
• R 3 is absent, hydrogen, halogen, cyano, alkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, aralkyl, heteroalykl, —O-alkyl, —O-aryl, —O-heteroaryl, aralkoxy, heteroaralkoxy, —S-alkyl, alkylene-O-alkyl, alkylene-CO 2 H, alkylene-CO 2 alkyl, alkylSO 2 , alkylenesulfonyl, alkylene-CO-amino, alkylene-CO-alkylamino, alkylene-CO-dialkylamino, alkylene-NH—CO 2 H, alkylene-NH—CO 2 alkyl —CO 2 alkyl, —OH, —C(O)-alkyl, —C(O)O-alkyl, —CONH 2 , —CO-alkylamino, —CO-
• aryl, heteroaryl, heterocyclo, or cycloalkyl any of which may be optionally substituted on carbon with 1, 2, or 3 groups selected form halogen, alkyl, O-alkyl, CO 2 H, CO 2 alkyl, halogen, amino, alkylamino, dialkylamino, —O-alkyl, alkylene-O-alkyl, alkylene-OH, or alkylene-CO 2 H, provided that
• R 4 is hydrogen, cyano, alkyl, aryl, heteroaryl, alkylene-O-alkyl, alkylene-OH, aryl, alkylene-O-alkyl, —CO 2 H, —CO 2 -alkyl, alkylene-CO 2 H, or alkylene-CO 2 -alkyl, alkylene-OC(O)R wherein R is hydrogen or alkyl; cycloalkyl, heterocycloalkyl, alkylene-NH 2 , alkylene-alkylamino, or alkylene-dialkylamino, any of which may be optionally substituted oh carbon with 1, 2, or 3 groups selected from OH, CO 2 H, CO 2 alkyl, halogen, amino, alkylamino, dialkylamino, —O-alkyl, alkylene-O-alkyl, alkylene-OH, or alkylene-CO 2 H;
• R 5 and R 6 are each independently selected from the group consisting of hydrogen, alkyl, alkylene-OH, aryl, alkylene-O-alkyl, —CO 2 H, CO 2 -alkyl, alkylene-OC(O)alkyl, cycloalkyl, heterocyclo, —C(O)-alkyl, —C(O)-aryl, C(O)-aralkyl, —C(O)-Oalkyl, —C(O)—Oaryl, —C(O)—Oaralkyl, alkylene-amino, alkylene-alkylamino, and alkylene-dialkylamino, any of which may be optionally substituted on carbon with halogen, alkyl, hydroxyl, CO 2 H, CO 2 alkyl or alkoxy; or
• R 5 and R 6 together with the nitrogen to which they are attached, may form a 3, 4, 5, or 6-membered saturated or unsaturated ring, optionally containing 1 or 2 additional heteroatoms selected from O, S, NH, or N-alkyl, and optionally substituted on carbon with halogen, alkyl, hydroxyl, or alkoxy;
• R 8 is hydrogen, alkyl or aryl
• n 0, 1, or 2.
• R 1 is aryl or heteroaryl, optionally substituted with 1, 2, or 3 groups selected from halo, alkyl, haloalkyl, -aryl, —CF 3 , —CN, —OH, or —O-alkyl.
• R 1 is aryl, e.g., phenyl, optionally substituted with 1 or 2 groups selected from —CF 3 , —CN, —OMe, —Cl or —F.
• R 1 is heteroaryl, e.g., thiophene or benzothiophene, optionally substituted with 1 or 2 groups selected from phenyl, —CF 3 , —CN, —OMe, —Cl or —F.
• R 1 is hydrogen.
• R 1 is phenyl.
• R 1 is pyridyl.
• R 1 is thiophenyl.
• R 1 is cyclohexyl.
• R 1 is cyclopentyl.
• A is a C 1 -C 10 alkylene. In some embodiments, A is a branched C 1 -C 10 alkylene. In other embodiments, A is n-octyl. In other embodiments, A is n-heptyl. In other embodiments, A is n-hexyl. In some embodiments, A is a C 1 -C 5 alkylene. In some embodiments, A is n-pentyl. In other embodiments, A is n-butyl. In still other embodiments, A is n-propyl. In other embodiments, A is ethyl. In still other embodiments, A is methyl.
• X 1 is O. In other embodiments, X 1 is S. In still other embodiments, X 1 is SO 2 . In some embodiments, X 1 is CH 2 . In other embodiments, X 1 is C ⁇ O. In still other embodiments, CH 2 O, wherein either the oxygen or the carbon may be attached to
• R′ is hydrogen. In other embodiments, R′ is methyl. In some embodiments, R′′ is hydrogen. In other embodiments, R′′ is methyl. In some embodiments, R′ and R′′ taken together with the carbon to which they are attached, is C ⁇ O, with the provision that only one of X 1 or R′ and R′′ taken together with the carbon may form C ⁇ O.
• R 3 is absent.
• R 3 is absent.
• R 3 would be considered absent, because there no substituents on the ring. In other embodiments, R 3 is halogen.
• R 4 is hydrogen. In other embodiments, R 4 is an alkyl, e.g., a C 1 -C 4 alkyl. For example, in some embodiments, R 4 is methyl. In some embodiments, R 4 is hydroxymethyl.
• R 5 is hydrogen. In some embodiments, R 6 is hydrogen. In some embodiments, R 5 is an alkyl, e.g., a C 1 -C 4 alkyl. In some embodiments, R 6 is an alkyl, e.g., a C 1 -C 4 alkyl.
• R can be hydrogen or alkyl.
• compounds of the present invention include compounds listed in the following table:
• n for each compound is 0, 1 or 2, as well as pharmaceutically acceptable salts, phosphate derivatives, phosphate mimics, or phosphate precursor analogs thereof.
• Compounds of the present invention include the following compounds:
• Compounds of the present invention further include the following compounds:
• mice Male C57Bl/6 mice were divided into groups of three. A control group received the 3% BSA vehicle only. The other groups received a single dose of either a specified dose of test compound in vehicle administered orally (PO) and intravenously (IV). After 6 hours, the mice were anesthetized with isoflurane and approximately 250 ⁇ L of blood was removed from the retroorbital sinus and collected in an EDTA microtainer, mixed with an anticoagulant and placed on a tilt table until complete blood count (CBC) analysis. Oral administration (10 mg/K) of these compounds induced increased lymphopenia versus the vehicle.
• PO vehicle administered orally
• IV intravenously
• a 10 mg/Kg oral dose of (S)-2-amino-2-(5-(4-(octyloxy)-3-(trifluoromethyl)phenyl)thiazol-2-yl)propan-1-ol produced a lymphopenia of 75% in this assay.
• the compounds of the invention selective for the S1P-1 receptor as compared to one or more of the other S1P receptors.
• one set of compounds includes compounds which are selective for the S1P-1 receptor relative to the S1P-3 receptor.
• Compounds selective for the S1P-1 receptor can be agonists of the S1P-1 receptor, significantly weaker agonists of one or more other receptors and/or antagonists of one or more other receptors.
• a compound is “selective” for the S1P-1 receptor relative to a second receptor, if the EC 50 of the compound for the second receptor is at least two-fold greater than the EC 50 for the S1P-1 receptor.
• the EC 50 of a compound is determined using the 35 S-GTP ⁇ S binding assay, as described in WO 03/061567, the entire contents of which are incorporated herein by reference. Additionally or alternatively, a compound is “selective” for the S1P-1 receptor relative to a second receptor, if the IC 50 of the compound for the second receptor is at least two-fold greater than the IC 50 for the S1P-1 receptor.
• the IC 50 of a compound is determined using the [ 33 P]sphingosine 1-phosphate binding assay, as described in Davis, M. D. et al., Sphingosine 1-Phosphate Analogs as Receptor Antagonists. J. Biol. Chem . (2005) 280:9833-9841, the entire contents of which are incorporated herein by this reference.
• agonist or “S1P-1 receptor agonist” as used herein include the compounds described herein which bind to and/or agonize the S1P-1 receptor.
• the S1P receptor agonists have an IC 50 for the S1P-1 receptor of about 100 nM-0.25 nM, about 50 nM-0.25 nM, about 25 nM-0.5 nM, about 100 nM or less, about 75 nM or less, about 50 nM or less, about 40 nM or less, about 30 nM or less, about 20 nM or less, about 10 nM or less, about 5 nM or less, about 1 nM or less, about 0.5 nM or less, or about 0.25 nM or less.
• the compounds' IC 50 for the S1P-1 receptor can be measured using the binding assays described in Example 13 or those described in WO 03/061567.
• Compounds of the invention generally had an IC 50 in the range of 100 ⁇ M (picomolar) to 100 M.
• Ranges intermediate to the above recited values are also intended to be part of this invention.
• ranges using a combination of any of the above recited values as upper and/or lower limits are intended to be included.
• the S1P receptor agonist has an IC 50 value for the S1P-3 receptor of about 10 nM-10,000 nM, about 100 nM-5000 nM, about 100 nM-3000 nM, about 10 nM or greater, about 20 nM or greater, about 40 nM or greater, about 50 nM or greater, about 75 nM or greater, or about 100 nM or greater.
• the S1P compound of the invention binds the S1P-3 receptor with an IC 50 of 1000 nM or greater, 2000 nM or greater, 3000 nM or greater, 5000 nM or greater, 10,000 nM or greater.
• the IC 50 for of S1P-3 receptor can be measured using the binding assays described herein or those described in WO 03/061567.
• the S1P receptor agonists described herein have an IC 50 value for the S1P-1 receptor that is about 5-fold lower, about 10-fold lower, about 20-fold lower, about 50-fold lower, about 100-fold lower, about 200-fold lower, about 500-fold lower or about 1000-fold lower than their IC 50 value for the S1P-3 receptor.
• Ranges intermediate to the above recited values are also intended to be part of this invention.
• ranges using a combination of any of the above recited values as upper and/or lower limits are intended to be included.
• plasmid DNA was transfected into HEK 293 T cells using the FuGENE 6 transfection protocol (publicly available from Roche). Briefly, subconfluent monolayers of HEK 293 T cells were transfected with the DNA mixture containing FuGENE 6 (using a 1:3 ratio). The dishes containing the cells were then placed in a tissue culture incubator (5% CO 2 , 37° C.). The cells were harvested 48 hours after addition of the DNA by scraping in HME buffer (in mM: 20 HEPES, 5 MgCl 2 , 1 EDTA, pH 7.4, 1 mM PMSF) containing 10% sucrose on ice, and disrupted using a Dounce homogenizer.
• HME buffer in mM: 20 HEPES, 5 MgCl 2 , 1 EDTA, pH 7.4, 1 mM PMSF
• [ 33 P]sphingosine 1-phosphate obtained from American Radiolabeled Chemicals, Inc was added to membranes in 200 ⁇ l in 96-well plates with assay concentrations of 2.5 pM [ 33 P]sphingosine 1-phosphate, 4 mg/ml BSA, 50 mM HEPES, pH 7.5, 100 mM NaCl, 5 mM MgCl2, and 5 ⁇ g of protein. Binding was performed for 60 minutes at room temperature with gentle mixing and terminated by collecting the membranes onto GF/B filter plates.
• Rat hepatoma cells stably expressing the human S1P1 receptor or Rat Basophilic Leukaemia cells (RBL) stably expressing human S1P3 receptor were grown to 80% confluency before being harvested into 10 ml Phospho-Buffered Saline (PBS) and centrifuged at 1200 rpm for 5 minutes.
• PBS Phospho-Buffered Saline
• the pellet was re-suspended and cells were homogenised within a glass Waring blender for 2 bursts of 15 secs in 200 mls of buffer (50 mM HEPES, 1 mM leupeptin, 25 ug/ml bacitracin, 1 mM EDTA, 1 mM PMSF, 2 uM pepstatin A).
• the blender was plunged into ice for 5 mins after the first burst and 10-40 mins after the final burst to allow foam to dissipate.
• the material was then spun at 500 g for 20 mins and the supernatant spun for 36 mins at 48,000 g.
• the pellet was resuspended in the same buffer as above but without PMSF and pepstatin A.
• the material was then forced through a 0.6 mm needle, made up to the required volume, (usually ⁇ 4 the volume of the original cell pellet), aliquoted and stored frozen at ⁇ 80° C.
• Human S1P1 rat hepatoma or S1P3 expressing RBL membranes (1.5 ug/well) were adhered to WGA-coated SPA beads (0.125 mg/well) in assay buffer (HEPES 20 mM, MgCl 2 3 mM, NaCl 100 mM and pH adjusted to 7.4 using KOH 5M, GDP 10 uM FAC and saponin 90 ug/well FAC was also added).
• assay buffer HEPS 20 mM, MgCl 2 3 mM, NaCl 100 mM and pH adjusted to 7.4 using KOH 5M, GDP 10 uM FAC and saponin 90 ug/well FAC was also added.
• test compounds were dissolved in DMSO at a concentration of 10 mM and were prepared in 100% DMSO using a 1 in 4 dilution step to provide 11 point dose response curves. The dilutions were transferred to the assay plates ensuring that the DMSO concentration was constant across the plate for all assays.
• the trifluoracetic acid salt of (S)-2-amino-2-(5-(4-(octyloxy)-3-(trifluoromethyl)phenyl)thiazol-2-yl)propyl dihydrogen phosphate had a pEC50 of 8.5 in the S1P1 assay and pEC50 of 6.5 in the S1P3 assay.
• the trifluoracetic acid salt of (S)-2-Amino-2-(5-(4-(octyloxy)-3-(trifluoromethyl)phenyl)-1,3,4-thiadiazol-2-yl)propyl dihydrogen phosphate had a pEC50 of 9.2 in the S1P1 assay and pEC50 of 6.1 in the S1P3 assay.
• the invention relates to a method for treating a subject suffering from a sphingosine 1-phosphate associated disorder, comprising administering to a subject an effective amount of a compound of the invention; that is, a compound of formula I or compounds otherwise described herein, such that the subject is treated for a sphingosine 1-phosphate associated disorder.
• sphingosine 1-phosphate associated disorder includes disorders, diseases or conditions which are associated with or caused by a misregulation in S1P receptor function and/or signaling or S1P receptor ligand function.
• the term also includes diseases, disorders or conditions which can be treated by administering to a subject an effective amount of a sphingosine 1-phosphate receptor agonist.
• Such disorders include disorders that are associated with an inappropriate immune response and conditions associated with an overactive immune response, e.g., autoimmune diseases.
• sphingosine 1-phosphate associated disorders include autoimmune diseases.
• sphingosine 1-phosphate associated disorders include inflammation.
• sphingosine 1-phosphate associated disorders include transplant rejection.
• sphingosine 1-phosphate associated disorders include acute respiratory distress syndrome (ARDS). In other embodiments, sphingosine 1-phosphate associated disorders include asthma. In yet other embodiments, sphingosine 1-phosphate associated disorders include any combination of the disorders listed herein.
• ARDS acute respiratory distress syndrome
• sphingosine 1-phosphate associated disorders include asthma. In yet other embodiments, sphingosine 1-phosphate associated disorders include any combination of the disorders listed herein.
• Treatment is defined as the application or administration of a therapeutic agent such as a compound of formula I to a subject who has a shingosine 1-phosphate associated disorder as described herein, with the purpose to cure, heal, alleviate, delay, relieve, alter, remedy, ameliorate, improve or affect the disease or disorder, or symptoms of the disease or disorder.
• treatment or “treating” is also used herein in the context of administering agents prophylactically.
• the efficacy of the compounds of the present invention can be measured by comparing a value, level, feature, characteristic, property, etc. to a “suitable control”.
• a “suitable control” is any control or standard familiar to one of ordinary skill in the art useful for comparison purposes.
• a “suitable control” is a value, level, feature, characteristic, property, etc. determined prior to administering a composition of the present invention.
• the immune response, etc. can be determined prior to introducing a compound of the invention into a cell or subject.
• a “suitable control” is a value, level, feature, characteristic, property, etc.
• a “suitable control” is a predefined value, level, feature, characteristic, property, etc.
• a “suitable control” can be a pre-defined level of binding to a specified S1P receptor.
• An additional embodiment of the invention pertains to a method for treating a subject suffering from a sphingosine 1-phosphate associated disorder, comprising administering to a subject a compound, such that the subject is treated for a sphingosine 1-phosphate associated disorder by a compound of the invention; that is, a compound of formulae I or compounds otherwise described herein.
• the present invention is also directed to a method of selectively treating a sphingosine 1-phosphate associated disorder, comprising administering to a subject an effective amount of a compound of the invention, e.g., compounds of any of Formulae I-VIII or compounds otherwise described herein, such that the subject is selectively treated for a sphingosine 1-phosphate associated disorder.
• the sphingosine 1-phosphate associated disorder is a sphingosine 1-phosphate-(1) associated disorder.
• the sphingosine 1-phosphate-(1) associated disorder is selectively treated as compared with a sphingosine 1-phosphate-(3) associated disorder.
• Another embodiment of the invention is a method of selectively treating a sphingosine 1-phosphate associated disorder, comprising administering to a subject a compound, such that the subject is selectively treated for a sphingosine 1-phosphate associated disorder by a compound of the invention, e.g., compounds of any of Formulae I-VIII or compounds otherwise described herein.
• the sphingosine 1-phosphate associated disorder is a sphingosine 1-phosphate-(1) associated disorder.
• the sphingosine 1-phosphate-(1) associated disorder is selectively treated as compared with a sphingosine 1-phosphate-(3) associated disorder.
• the present invention provides a method of treating a condition associated with an activated immune system.
• diseases or disorders include multiple sclerosis as well as rejection of transplanted organs, tissue or cells; graft-versus-host diseases brought about by transplantation; autoimmune syndromes including rheumatoid arthritis; systemic lupus erythematosus; antiphospholipid syndrome; Hashimoto's thyroiditis; lymphocytic thyroiditis; myasthenia gravis; type I diabetes; uveitis; episcleritis; scleritis; Kawasaki's disease, uveo-retinitis; posterior uveitis; uveitis associated with Behcet's disease; uveomeningitis syndrome; allergic encephalomyelitis; chronic allograft vasculopathy; post-infectious autoimmune diseases including rheumatic fever and post-infectious glomerulonephritis; inflammatory and hyperproliferative skin diseases; ps
• the term “subject” includes warm-blooded animals, e.g., mammals, including humans, cats, dogs, horses, bears, lions, tigers, ferrets, rabbits, mice, cows, sheep, pigs, etc.
• the subject is a primate.
• the primate is a human.
• administering includes dispensing, delivering or applying a compound of the invention in a pharmaceutical formulation (as described herein), to a subject by any suitable route for delivery of the compound to the desired location in the subject, including delivery by either the parenteral or oral route, intramuscular injection, subcutaneous/intradermal injection, intravenous injection, buccal administration, topical delivery, transdermal delivery and administration by the rectal, colonic, vaginal, intranasal or respiratory tract route.
• the term “effective amount” includes an amount effective, at dosages and for periods of time necessary, to achieve the desired result, e.g., sufficient to treat the condition in a subject.
• An effective amount of a compound of the invention, as defined herein, may vary according to factors such as the disease state, age, and weight of the subject, and the ability of the compound to elicit a desired response in the subject. Dosage regimens may be adjusted to provide the optimum therapeutic response.
• An effective amount is also one in which any toxic or detrimental effects (e.g., side effects) of the compound are outweighed by the therapeutically beneficial effects.
• a therapeutically effective amount of a compound of the invention may range from about 0.001 to 30 mg/kg body weight, for example, about 0.01 to 25 mg/kg body weight, for example, about 0.1 to 20 mg/kg body weight. It is to be understood that all values and ranges between those listed are intended to be encompassed by the present invention. The skilled artisan will appreciate that certain factors may influence the dosage required to effectively treat a subject, including but not limited to the severity of the disease or disorder, previous treatments, the general health and/or age of the subject, and other diseases present. Moreover, treatment of a subject with a therapeutically effective amount of a compound of the invention can include a single treatment or, for example, can include a series of treatments. It will also be appreciated that the effective dosage of the compound used for treatment may increase or decrease over the course of a particular treatment.
• the methods of the invention further include administering to a subject a therapeutically effective amount of a compound of the invention in combination with another pharmaceutically active compound known to treat the disease or condition, e.g., an immunomodulatory agent or an anti-inflammatory agent.
• a pharmaceutically active compound known to treat the disease or condition
• Pharmaceutically active compounds that may be used depend upon the condition to be treated, but include as examples cyclosporin, rapamycin, FK506, methotrexate, etanercept, infliximab, adalimumab, non-steroidal anti-inflammatory agents, cyclooxygenase-2-inhibitors, such as celecoxib and rofecoxib, and corticosteroids.
• the present invention also provides pharmaceutically acceptable formulations and compositions comprising one or more compounds of the invention; that is, compounds of formula I or compounds otherwise described herein.
• the compound of the invention is present in the formulation in a therapeutically effective amount; that is, an amount effective to treat a sphingosine 1-phosphate associated disorder.
• the invention pertains to a pharmaceutical composition
• a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention; that is, compounds of formula I or compounds otherwise described herein, and a pharmaceutically acceptable carrier.
• the invention is directed to a packaged pharmaceutical composition
• a packaged pharmaceutical composition comprising a container holding a therapeutically effective amount of a compound of the invention; that is, compounds of formula I or compounds otherwise described herein; and instructions for using the compound to treat a sphingosine 1-phosphate associated disorder in a subject.
• the term “container” includes any receptacle for holding the pharmaceutical composition.
• the container is the packaging that contains the pharmaceutical composition.
• the container is not the packaging that contains the pharmaceutical composition, i.e., the container is a receptacle, such as a box or vial that contains the packaged pharmaceutical composition or unpackaged pharmaceutical composition and the instructions for use of the pharmaceutical composition.
• packaging techniques are well known in the art. It should be understood that the instructions for use of the pharmaceutical composition may be contained on the packaging containing the pharmaceutical composition, and as such the instructions form an increased functional relationship to the packaged product. However, it should be understood that the instructions can contain information pertaining to the compound's ability to perform its intended function, e.g., treating, preventing, or reducing a sphingosine 1-phosphate associated disorder in a subject.
• Another embodiment of the invention relates to a packaged pharmaceutical composition
• a packaged pharmaceutical composition comprising a container holding a therapeutically effective amount of a compound of the invention; that is, a compound of formula I or compounds otherwise described herein, and instructions for using the compound to selectively treat a sphingosine 1-phosphate associated disorder in a subject.
• Such pharmaceutically acceptable formulations typically include one or more compounds of the invention as well as one or more pharmaceutically acceptable carriers and/or excipients.
• pharmaceutically acceptable carrier includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like that are physiologically compatible. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the compounds of the invention, use thereof in the pharmaceutical compositions is contemplated.
• Supplementary pharmaceutically active compounds known to treat transplant or autoimmune disease i.e., immunomodulatory agents and anti-inflammatory agents, as described above, can also be incorporated into the compositions of the invention.
• Suitable pharmaceutically active compounds that may be used can be found in Harrison's Principles of Internal Medicine.
• a pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration.
• routes of administration include parenteral, e.g., intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (topical), transmucosal, and rectal administration.
• Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide.
• the parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.
• compositions suitable for injection include sterile aqueous solutions (where water soluble) or dispersions, or sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions.
• suitable carriers include physiological saline, bacteriostatic water, Cremophor EITM (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS).
• the pharmaceutical composition must be sterile and should be fluid to the extent that easy syringability exists. It must also be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fingi.
• the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof.
• the proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
• Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like.
• isotonic agents for example, sugars, polyalcohols such as mannitol, sorbitol, or sodium chloride in the composition.
• Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.
• Sterile injectable solutions can be prepared by incorporating the compound of the invention in the required amount in an appropriate solvent with one or a combination of the ingredients enumerated above, as needed, followed by filtered sterilization.
• dispersions are prepared by incorporating the compound into a sterile vehicle which contains a basic dispersion medium and the required other ingredients from those enumerated above.
• the preferred methods of preparation are vacuum drying and freeze-drying which yields a powder of the compound plus any additional desired ingredient from a previously sterile-filtered solution thereof.
• Oral compositions generally include an inert diluent or an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the compound of the invention can be incorporated with excipients and used in the form of tablets, troches, or capsules. Oral compositions can also include an enteric coating. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition.
• the tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.
• a binder such as microcrystalline cellulose, gum tragacanth or gelatin
• an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch
• a lubricant such as magnesium stearate or Sterotes
• a glidant such as colloidal silicon dioxide
• the compounds of the invention are delivered in the form of an aerosol spray from a pressured container or dispenser which contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer.
• a suitable propellant e.g., a gas such as carbon dioxide, or a nebulizer.
• Systemic administration can also be by transmucosal or transdermal means.
• penetrants appropriate to the barrier to be permeated are used in the formulation.
• penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives.
• Transmucosal administration can be accomplished through the use of nasal sprays or suppositories.
• the compounds of the invention are formulated into ointments, salves, gels, or creams as generally known in the art.
• compositions can also be prepared in the form of suppositories (e.g., with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.
• suppositories e.g., with conventional suppository bases such as cocoa butter and other glycerides
• retention enemas for rectal delivery.
• the compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems.
• a controlled release formulation including implants and microencapsulated delivery systems.
• Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art.
• the materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc.
• Liposomal suspensions can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Pat. No. 4,522,811, U.S. Pat. No. 5,455,044 and U.S. Pat. No. 5,576,018, and U.S. Pat. No. 4,883,666, the contents of all of which are incorporated herein by reference.
• the compounds of the invention can also be incorporated into pharmaceutical compositions which allow for the sustained delivery of the compounds to a subject for a period of at least several weeks to a month or more.
• Such formulations are described in published PCT application no. WO 02/74247, incorporated herein by reference.
• Dosage unit form refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of a compound of the invention calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.
• the specification for the unit dosage forms of the invention are dictated by and directly dependent on the unique characteristics of the compound and the particular therapeutic effect to be achieved, and the limitations inherent in the art of compounding such compounds for the treatment of individuals.
• compound 4 was synthesized from (S)-2-(tert-butoxycarbonylamino)-3-hydroxy-2-methylpropanoic acid in three steps in overall 52-64% yield.
• a synthesis of (R)-3-(tert-butoxycarbonyl)-2,2,4-trimethyloxazolidine-4-carboxylic acid is described in Clemens, J. J.; Davis, M. D.; Lynch, K. R.; Macdonald, T. L. Bioorg. Med. Chem. Lett. 2005, 15, 3568-3572.
• Compound 5 was synthesized from 2-amino-2-(hydroxymethyl)propane-1,3-diol in five steps in overall 30% yield, also as described in Clemens, J.
• the purified residue was dissolved in THF (40 mL) and to the solution was added LiOH (1.15 g, 1.20 equiv) in H 2 O (20 mL). The solution was heated at reflux for 6-18 hours, then concentrated in vacuo to remove most of the THF. The solution was diluted with H 2 O (150 mL) and washed with Et 2 O (2 ⁇ 150 mL). The aqueous layer was cooled to 0° C. then acidified to a pH of approximately 3 using concentrated HCl, then extracted with EtOAc (2 ⁇ 200 mL).
• the diol 8b was prepared from carboxylate S and amino-acetophenone 3 analogously to thiazole 8a in 35% yield over three steps.
• the obtained phospho-diester intermediate was reacted with excess bromotrimethylsilane (10.0-20.0 equiv) in dry CH 2 Cl 2 at room temperature over a period of 6-10 hours to afford the final phosphate which was purified by reverse-phase preparative HPLC after evaporation of the solvent and excess reagent.
• the desired alkyne is dissolved in ethanol and a heterogeneous mixture of palladium on carbon is added. The reaction is shaken for 2 hours under 40 psi of H 2 . Filtration through celite and removal of the solvent in vacuo gives the desired product.
• the title compound was prepared from 4-fluoro-3-(trifluoromethyl)benzoic acid (1a) in >99% (5.65 g) yield.
• HPLC retention time on a C8(2) column (30 ⁇ 3.00 mm, 3 ⁇ ) was 2.53 min with gradient 20-98% acetonitrile-H 2 O (0.1% TFA) in 4.0 min as mobile phase.
• Benzoic acid 2 (1.0 equiv) was stirred with HATU (1.1 equiv) and DIEA (3.0 equiv) in DCM-DMF (2:1) for 20 minutes. The solution was then added to a solution of hydrazine mono-hydrate (3.0-5.0) in DCM-DMF (2:1). The reaction mixture was stirred at rt for 1 hour, then diluted with ethyl acetate and washed with 10% NH 4 Cl (2 ⁇ ) and saturated NaCl (1 ⁇ ). The organic layer was dried over MgSO 4 , filtered, and the solvent was removed in vacuo to afford benzohydrazide 3.
• the phenyl-thiazole 6a was prepared through two different protocols (A and B) from 5c:
• the title compound was prepared from 4-(5-(4-hydroxy-3-(trifluoromethyl)phenyl)-1,3,4-thiadiazol-2-yl)-2,2,4-trimethyoxyazolidine-3-carboxylate 6a in 50% (306 mg) yield.
• HPLC retention time on a Synergi-Max RP column (2 ⁇ 20 mm, 2 ⁇ L) is 1.32 min with gradient 40-99% acetonitrile-H 2 O (0.1% TFA) in 2 min as mobile phase.
• the title compound was prepared from 4-(5-(4-hydroxy-3-(trifluoromethyl)phenyl)-1,3,4-thiadiazol-2-yl)-2,2,4-trimethyoxyazolidine-3-carboxylate 6a in 58% (35 mg) yield.
• HPLC retention time on a Synergi-Max RP column (2 ⁇ 20 mm, 2 ⁇ L) is 0.70 min with gradient 40-99% acetonitrile-H 2 O (0.1% TFA) in 2 min as mobile phase.
• the title compound was prepared from 4-(5-(4-hydroxy-3-(trifluoromethyl)phenyl)-1,3,4-thiadiazol-2-yl)-2,2,4-trimethyoxyazolidine-3-carboxylate 6a in 51% (30.7 mg) yield.
• HPLC retention time on a Synergi-Max RP column (2 ⁇ 20 mm, 2 ⁇ L) is 0.68 min with gradient 40-99% acetonitrile-H 2 O (0.1% TEA) in 2 min as mobile phase.
• the title compound was prepared from 4-(5-(4-hydroxy-3-(trifluoromethyl)phenyl)-1,3,4-thiadiazol-2-yl)-2,2,4-trimethyoxyazolidine-3-carboxylate 6a in 64% (39 mg) yield.
• HPLC retention time on a Synergi-Max RP column (2 ⁇ 20 mm, 2 ⁇ L) is 0.77 min with gradient 50-98% acetonitrile-H 2 O (0.1% TFA) in 2 min as mobile phase.
• the title compound was prepared from 4-(5-(4-hydroxy-3-(trifluoromethyl)phenyl)-1,3,4-thiadiazol-2-yl)-2,2,4-trimethyoxyazolidine-3-carboxylate 6a in 19% (10 mg) yield.
• HPLC retention time on a Synergi-Max RP column (2 ⁇ 20 mm, 2 ⁇ L) is 1.37 min with gradient 20-95% acetonitrile-H 2 O (0.1% TFA) in 2 min as mobile phase.
• the title compound was prepared from 4-(5-(4-hydroxy-3-(trifluoromethyl)phenyl)-1,3,4-thiadiazol-2-yl)-2,2,4-trimethyoxyazolidine-3-carboxylate 6a in 12% (6.2 mg) yield.
• HPLC retention time on a Synergi-Max RP column (2 ⁇ 20 mm, 2 ⁇ L) is 1.45 min with gradient 20-95% acetonitrile-H 2 O (0.1% TFA) in 2 min as mobile phase.
• the title compound was prepared from 4-(5-(4-hydroxy-3-(trifluoromethyl)phenyl)-1,3,4-thiadiazol-2-yl)-2,2,4-trimethyoxyazolidine-3-carboxylate 6a in 12% (6.0 mg) yield.
• HPLC retention time on a Synergi-Max RP column (2 ⁇ 20 mm, 2 ⁇ L) is 1.26 min with gradient 30-99% acetonitrile-H 2 O (0.1% TFA) in 2 min as mobile phase.
• the title compound was prepared from 4-(5-(4-hydroxy-3-(trifluoromethyl)phenyl)-1,3,4-thiadiazol-2-yl)-2,2,4-trimethyoxyazolidine-3-carboxylate 6a in 41% (232 mg) yield.
• HPLC retention time on a Synergi-Max RP column (2 ⁇ 20 mm, 2 ⁇ L) is 1.38 min with gradient 20-95% acetonitrile-H 2 O (0.1% TFA) in 2 min as mobile phase.
• the title compound was prepared from 4-(5-(4-hydroxy-3-(trifluoromethyl)phenyl)-1,3,4-thiadiazol-2-yl)-2,2,4-trimethyoxyazolidine-3-carboxylate 6a in 29% (184 mg) yield.
• HPLC retention time on a Synergi-Max RP column (2 ⁇ 20 mm, 2 ⁇ L) is 1.67 min with gradient 20-95% acetonitrile-H 2 O (0.1% TFA) in 2 min as mobile phase.
• the title compound was prepared from 4-(5-(4-hydroxy-3-(trifluoromethyl)phenyl)-1,3,4-thiadiazol-2-yl)-2,2,4-trimethyoxyazolidine-3-carboxylate 6a in 12% (7.8 mg) yield.
• HPLC retention time on a Synergi-Max RP column (2 ⁇ 20 mm, 2 ⁇ L) is 1.64 min with gradient 20-95% acetonitrile-H 2 O (0.1% TFA) in 2 min as mobile phase.
• the title compound was prepared from 4-(5-(4-hydroxy-3-(trifluoromethyl)phenyl)-1,3,4-thiadiazol-2-yl)-2,2,4-trimethyoxyazolidine-3-carboxylate 6a in 41% (19 mg) yield.
• HPLC retention time on a Synergi-Max RP column (2 ⁇ 20 mm, 2 ⁇ L) is 1.79 min with gradient 50-98% acetonitrile-H 2 O (0.1% TFA) in 2 min as mobile phase.
• the title compound was prepared from 4-(5-(4-hydroxy-3-(trifluoromethyl)phenyl)-1,3,4-thiadiazol-2-yl)-2,2,4-trimethyoxyazolidine-3-carboxylate 6a in 47% (27 mg) yield.
• HPLC retention time on a Synergi-Max RP column (2 ⁇ 20 min, 2 ⁇ L) is 1.66 min with gradient 50-98% acetonitrile-H 2 O (0.1% TFA) in 2 min as mobile phase.
• the title compound was prepared from 4-(5-(4-hydroxy-3-(trifluoromethyl)phenyl)-1,3,4-thiadiazol-2-yl)-2,2,4-trimethyoxyazolidine-3-carboxylate 6a in 35% (22 mg) yield.
• HPLC retention time on a Synergi-Max RP column (2 ⁇ 20 mm, 2 ⁇ L) is 1.68 min with gradient 20-95% acetonitrile-H 2 O (0.1% TFA) in 2 min as mobile phase.
• the title compound was prepared from 4-(5-(4-hydroxy-3-(trifluoromethyl)phenyl)-1,3,4-thiadiazol-2-yl)-2,2,4-trimethyoxyazolidine-3-carboxylate 6a in 8% (5 mg) yield.
• HPLC retention time on a Synergi-Max RP column (2 ⁇ 20 mm, 2 ⁇ L) is 1.59 min with gradient 20-95% acetonitrile-H 2 O (0.1% TFA) in 2 min as mobile phase.
• Acyl-benzohydrazide 5 could also be oxidized with mCPBA to afford acyl-benzohydrazide 8 before treatment with Lawesson's reagent and deprotection. Reaction of the alcohol 7 with diethyl chlorophosphate followed by deprotection with TMSBr gave the corresponding phosphate.

Priority Applications (1)

Applications Claiming Priority (6)

Publications (1)

Family

ID=38952062

Family Applications (2)

Family Applications Before (1)

Country Status (18)

Families Citing this family (31)

Citations (5)

Family Cites Families (7)

• 2007
  • 2007-07-31 AR ARP070103371A patent/AR062156A1/es not_active Application Discontinuation
  • 2007-07-31 TW TW096127869A patent/TW200823182A/zh unknown
  • 2007-08-01 JP JP2009522874A patent/JP2009545599A/ja active Pending
  • 2007-08-01 PE PE2007001000A patent/PE20080730A1/es not_active Application Discontinuation
  • 2007-08-01 BR BRPI0714512-8A patent/BRPI0714512A2/pt not_active IP Right Cessation
  • 2007-08-01 MX MX2009001188A patent/MX2009001188A/es unknown
  • 2007-08-01 US US11/888,909 patent/US7759370B2/en not_active Expired - Fee Related
  • 2007-08-01 EP EP07836442A patent/EP2046746A2/en not_active Withdrawn
  • 2007-08-01 AU AU2007281491A patent/AU2007281491A1/en not_active Abandoned
  • 2007-08-01 KR KR1020097004192A patent/KR20090033912A/ko not_active Application Discontinuation
  • 2007-08-01 WO PCT/US2007/017282 patent/WO2008016692A2/en active Application Filing
  • 2007-08-01 US US12/375,682 patent/US20100009936A1/en not_active Abandoned
  • 2007-08-01 CA CA002659473A patent/CA2659473A1/en not_active Abandoned
  • 2007-08-01 EA EA200970173A patent/EA200970173A1/ru unknown
• 2009
  • 2009-01-19 IL IL196595A patent/IL196595A0/en unknown
  • 2009-01-30 CO CO09008880A patent/CO6150145A2/es unknown
  • 2009-02-11 MA MA31631A patent/MA30639B1/fr unknown
  • 2009-02-16 NO NO20090739A patent/NO20090739L/no not_active Application Discontinuation
  • 2009-02-20 CR CR10628A patent/CR10628A/es not_active Application Discontinuation

Patent Citations (5)

Also Published As

Similar Documents

Legal Events